ENYO Pharma

ENYO Pharma (Lyon, France) is a clinical-stage biopharmaceutical company. The company is developing a portfolio of drug candidates to improve quality of life and
avoid end stage renal disease and dialysis for patients with rare and common kidney diseases. Its lead candidate Vonafexor, as well as fast follower EYP651, is a once-daily oral treatment. Both compounds have fibrolytic and anti-inflammatory properties that are broadly applicable across several renal diseases. ENYO Pharma is currently starting its Phase 2 ALPESTRIA-1 study to confirm Vonafexor’s effect on renal function (eGFR) in Alport Syndrome, as was seen in its Phase 2 LIVIFY study of patients with both kidney impairment and fibrotic liver disease. ENYO Pharma is also preparing additional Phase 2 trials to extend its franchise to other renal diseases.